JPH11511984A - 細胞周期チェックポイント遺伝子 - Google Patents
細胞周期チェックポイント遺伝子Info
- Publication number
- JPH11511984A JPH11511984A JP9510985A JP51098597A JPH11511984A JP H11511984 A JPH11511984 A JP H11511984A JP 9510985 A JP9510985 A JP 9510985A JP 51098597 A JP51098597 A JP 51098597A JP H11511984 A JPH11511984 A JP H11511984A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- rad3
- atr
- polynucleotide
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.配列番号:1またはその相補配列と選択的にハイブリダイズすることがで きる、実質的に単離されたフォームのポリヌクレオチド。 2.配列番号:1で示されるポリヌクレオチドまたはその断片を含む、請求の 範囲第1項記載のポリヌクレオチド。 3.請求の範囲第1または2項記載のポリヌクレオチドの少なくとも15ヌク レオチドの断片を含むポリヌクレオチドプローブ。 4.配列番号:3またはその相補配列を含む、実質的に単離されたフォームの ポリヌクレオチド。 5.配列番号:2または4のポリペプチド、実質的にそれらと相同性を有する ポリペプチド、または配列番号:2のポリペプチドの断片のいずれかで示される 配列を含む、実質的に単離されたフォームのポリペプチド。 6.請求の範囲第5項記載のポリペプチドをコードする、実質的に単離された フォームのポリヌクレオチド。 7.請求の範囲第1、2または6項記載のポリヌクレオチドを有するベクター 。 8.配列番号:2またはその断片のポリペプチドに結合することができる抗体 。 9.ヒトまたは動物体試料中における請求の範囲第1項記載のポリヌクレオチ ドの有無を検出するための方法であって、以下の工程すなわち、 DNAまたはRNAを含有するヒトまたは動物体試料を、ハイビリダイゼーシ ョン条件下で請求の範囲第1項記載のポリヌクレオチドまたはプライマーを含む プローブに接触せしめ、そして プローブと試料中の核酸との間に形成される二本鎖分子を検出する工程を含む 方法。 10.生物学的試料中に存在する請求の範囲第6項記載のポリペプチドを検出す る方法であって、以下の工程すなわち、 (a)請求の範囲第7項記載の抗体を準備し、 (b)抗体−抗原複合体の形成を許容する条件下で、該抗体と共に生物学的試 料をインキュベートし、そして (c)該抗体を含む抗体−抗原複合体が形成されるか否かを判定する 工程を含む方法。 11.抗ガン療法のための候補物質をスクリーニングするためのアッセイ方法で あって、以下の工程すなわち、 (a)脂質キナーゼ活性を有する本発明のポリペプチド及び該キナーゼのため の基質を、かかるキナーゼ活性が基質に対して作用するような条件下に試薬と共 に準備し、 (b)候補物質に該ポリペプチド及び基質を接触せしめ、 (c)該ポリペプチドのキナーゼ活性の減少の程度を測定し、そして (d)活性の減少をもたらす候補物質を選択する 工程を含むアッセイ方法。 12.抗ガン療法のための候補物質をスクリーニングするためのアッセイ方法で あって、以下の工程すなわち、 (a)(i)本発明のポリペプチドと、第1のポリペプチドと同じかまたは異 なりうる本発明の別のポリペプチドとを、第1のポリペプチドと第2のポリペプ チドとが結合して複合体を形成することを許容する条件下でインキュベートし、 (ii)しかして形成された複合体を候補物質と接触せしめるか、または (a)本発明のポリペプチドと、第1のポリペプチドと同じかまたは異なりう る本発明の他のポリペプチドとを、候補物質の存在下に、第1のポリペプチドが 第2のポリペプチドと結合して複合体を形成することを許容する条件下でインキ ュベートし、 (b)第1のポリペプチドと第2のポリペプチドとの結合を候補物質が阻害 するか否かを判定し、そして (c)第1のポリペプチドと第2のポリペプチドとの結合を阻害する候補物 質を選択する 工程を含む方法。 13.前記第1のポリペプチドと前記第2のポリペプチドとが識別されうる請求 の範囲第12項記載の方法。 14.請求の範囲第11乃至13項のいずれかに記載の方法によって選択された 候補物質の治療上有効な量を患者に投与することを含む、患者におけるガンの治 療方法。 15.請求の範囲第11乃至13項のいずれかに記載の方法によって選択された 候補物質の治療上有効な量を患者に投与することを含む、患者における化学療法 及び/または放射線療法へのガン細胞の感受性を高める方法。 16.ガンの治療のための、請求の範囲第11乃至13項のいずれかに記載の方 法によって選択された候補物質の使用。 17.化学療法及び/または放射線療法へのガン細胞の感受性を高めるための、 請求の範囲第11乃至13項のいずれかに記載の方法によって選択された候補物 質の使用。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9518220.0 | 1995-09-06 | ||
GBGB9518220.0A GB9518220D0 (en) | 1995-09-06 | 1995-09-06 | Checkpoint gene |
PCT/GB1996/002197 WO1997009433A1 (en) | 1995-09-06 | 1996-09-06 | Cell-cycle checkpoint genes |
CZ1998656A CZ292808B6 (cs) | 1995-09-06 | 1996-09-06 | ATR polypeptid, polynukleotid, který jej kóduje, způsoby jejich detekce, vektor a protilátka |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11511984A true JPH11511984A (ja) | 1999-10-19 |
Family
ID=25746866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9510985A Ceased JPH11511984A (ja) | 1995-09-06 | 1996-09-06 | 細胞周期チェックポイント遺伝子 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0856058B1 (ja) |
JP (1) | JPH11511984A (ja) |
CN (1) | CN1201492A (ja) |
AU (1) | AU730220B2 (ja) |
BR (1) | BR9610168A (ja) |
CA (1) | CA2231190A1 (ja) |
CZ (1) | CZ292808B6 (ja) |
GB (1) | GB9518220D0 (ja) |
IL (1) | IL123553A0 (ja) |
NO (1) | NO980957L (ja) |
PL (1) | PL325427A1 (ja) |
SK (1) | SK30298A3 (ja) |
WO (1) | WO1997009433A1 (ja) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997018323A2 (en) * | 1995-11-16 | 1997-05-22 | Icos Corporation | Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity |
GB9718952D0 (en) * | 1997-09-05 | 1997-11-12 | Medical Res Council | Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods |
ATE331791T1 (de) | 1998-02-23 | 2006-07-15 | Icos Corp | Phosphodiesterase 10 |
US6479256B1 (en) | 1998-03-04 | 2002-11-12 | Icos Corporation | Lectomedin materials and methods |
US6071691A (en) * | 1998-04-27 | 2000-06-06 | Oregon Health Science University | Materials and methods for modulating differentiation |
US6790950B2 (en) | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
KR20010112937A (ko) | 1999-04-09 | 2001-12-22 | 로렌스 티. 마이젠헬더 | 항균성 백신 조성물 |
US6670167B1 (en) * | 1999-11-01 | 2003-12-30 | Agouron Pharmaceuticals, Inc. | Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof |
US6344549B1 (en) | 1999-10-14 | 2002-02-05 | Icos Corporation | ATR-2 cell cycle checkpoint |
EP1222273A2 (en) | 1999-10-22 | 2002-07-17 | PHARMACIA & UPJOHN COMPANY | Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
WO2001038533A2 (en) | 1999-11-24 | 2001-05-31 | Pharmacia & Upjohn Company | G protein-coupled receptor-like receptors and modulators thereof |
US6498026B2 (en) | 2000-02-25 | 2002-12-24 | Hercules Incorporated | Variant galactose oxidase, nucleic acid encoding same, and methods of using same |
WO2001090326A2 (en) | 2000-05-22 | 2001-11-29 | Pharmacia & Upjohn Company | Novel matrix metalloproteinases |
US6686449B2 (en) | 2000-06-30 | 2004-02-03 | Pharmacia & Upjohn Company | Mutant presenilin 1 polypeptides |
WO2002002639A2 (en) | 2000-07-05 | 2002-01-10 | Pharmacia & Upjohn Company | Human ion channels |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7098007B2 (en) | 2001-08-22 | 2006-08-29 | California Institute Of Technology | Cloning and functional assays of Xenopus ATR |
AU2003219753A1 (en) * | 2002-02-13 | 2003-09-04 | University Of Rochester | Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors |
WO2004045532A2 (en) | 2002-11-15 | 2004-06-03 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
AU2005247858A1 (en) | 2004-04-14 | 2005-12-08 | Monell Chemical Senses Center | Taste receptors of the T1R family from domestic dog |
EP1756149B1 (en) | 2004-05-24 | 2013-09-04 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Live, oral vaccine for protection against shigella dysenteriae serotype 1 |
US20060134698A1 (en) | 2004-12-20 | 2006-06-22 | Evanston Northwestern Healthcare Research Institute | Methods for treating cardiac disease by modifying an N-terminal domain of troponin I |
PT2298815E (pt) | 2005-07-25 | 2015-07-16 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
EP1984024A2 (en) | 2006-01-05 | 2008-10-29 | Novartis AG | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
CA3149553C (en) | 2006-06-12 | 2023-11-21 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
WO2009047567A1 (en) * | 2007-10-10 | 2009-04-16 | University Of Sheffield | Assay for identifying agents which inhibit the atr and/or dna-pk pathways |
CA2719924C (en) | 2008-04-11 | 2017-10-03 | Philip Tan | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
KR20190064664A (ko) | 2008-10-02 | 2019-06-10 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd86 길항제 다중-표적 결합 단백질 |
WO2011079308A2 (en) | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
AU2010343057B2 (en) | 2009-12-29 | 2017-02-23 | Aptevo Research And Development Llc | Heterodimer binding proteins and uses thereof |
RU2447899C2 (ru) | 2010-05-27 | 2012-04-20 | Михаил Валентинович Филатов | Композиция для лечения гепатита с и способ лечения гепатита с |
CN104685060B (zh) | 2012-07-13 | 2019-11-01 | 凯利斯塔公司 | 生物精炼系统、其方法和组合物 |
AU2013342143B2 (en) | 2012-11-09 | 2017-08-10 | Calysta, Inc. | Compositions and methods for biological production of fatty acid derivatives |
EP3011017B1 (en) | 2013-06-18 | 2019-09-11 | Calysta, Inc. | Compositions and methods for biological production of lactate from c1 compounds using lactate dehydrogenase transformants |
EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
SG10201805672UA (en) | 2014-01-02 | 2018-08-30 | Trelys Inc | Compositions and methods for biological production of amino acids in hydrogenotrophic microorganisms |
RU2016129316A (ru) | 2014-01-16 | 2018-02-21 | Калиста, Инк. | Углевод-обогащенные рекомбинантные микроорганизмы |
EP3102703A2 (en) | 2014-02-07 | 2016-12-14 | Effector Therapeutics Inc. | Methods for treating fibrotic disease |
US20170247692A1 (en) | 2014-02-07 | 2017-08-31 | Effector Therapeutics, Inc. | Compositions and methods for treating neurological disorders |
BR112016021345A8 (pt) | 2014-03-17 | 2022-07-05 | Tapimmune Inc | Composições de vacina de molécula de ácido nucleico e usos das mesmas |
CA2946846A1 (en) | 2014-05-15 | 2015-11-19 | Calysta, Inc. | Methods for biological production of very long carbon chain compounds |
CN107074970B (zh) | 2014-08-04 | 2021-07-30 | 弗雷德哈钦森癌症研究中心 | 特异性针对wt-1的t细胞免疫疗法 |
US10828352B2 (en) | 2014-10-27 | 2020-11-10 | Fred Hutchinson Cancer Research Center | Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy |
EP3292208B1 (en) | 2015-05-06 | 2020-08-19 | Trelys, Inc. | Compositions and methods for biological production of methionine |
WO2016187486A1 (en) | 2015-05-19 | 2016-11-24 | Fred Hutchinson Cancer Research Center | Biomarkers and uses thereof for selecting pancreas cancer intervention |
UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
WO2017112944A1 (en) | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
WO2017117052A1 (en) | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
CA3010977A1 (en) | 2016-01-11 | 2017-07-20 | Zoetis Services Llc | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
JP7033549B2 (ja) | 2016-05-04 | 2022-03-10 | フレッド ハッチンソン キャンサー リサーチ センター | 細胞に基づくネオ抗原ワクチンおよびその使用 |
WO2017193104A1 (en) | 2016-05-06 | 2017-11-09 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for mart-1 |
AU2017331362A1 (en) | 2016-09-23 | 2019-03-14 | Fred Hutchinson Cancer Center | TCRs specific for minor histocompatibility (H) antigen HA-1 and uses thereof |
ES2912269T3 (es) | 2016-09-27 | 2022-05-25 | Cero Therapeutics Inc | Moléculas de receptor de engullimiento quimérico |
WO2018090057A1 (en) | 2016-11-14 | 2018-05-17 | Fred Hutchinson Cancer Research Center | High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof |
JP7129978B2 (ja) | 2016-12-14 | 2022-09-02 | ゾエティス・サービシーズ・エルエルシー | 豚繁殖・呼吸障害症候群(prrs)ウイルスの欧州株に対抗する離乳前の効果的なワクチン接種 |
EP3580568A1 (en) | 2017-02-09 | 2019-12-18 | Fred Hutchinson Cancer Research Center | Biomarkers and uses thereof for selecting immunotherapy intervention |
CN110582299A (zh) | 2017-03-15 | 2019-12-17 | 弗雷德哈钦森癌症研究中心 | 高亲和力mage-a1特异性tcr及其用途 |
CA3064000A1 (en) | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
BR112020001180A2 (pt) | 2017-07-20 | 2020-09-08 | Aptevo Research And Development Llc | proteínas de ligação a antígenos que se ligam a 5t4 e 4-1bb e composições e métodos relacionados |
WO2019055862A1 (en) | 2017-09-14 | 2019-03-21 | Fred Hutchinson Cancer Research Center | HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF |
CN111386284A (zh) | 2017-09-26 | 2020-07-07 | 森罗治疗公司 | 嵌合吞噬受体分子和使用方法 |
WO2019109047A1 (en) | 2017-12-01 | 2019-06-06 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
EP3710484B1 (en) | 2017-12-20 | 2023-10-25 | Harbour Biomed (Shanghai) Co., Ltd | Antibodies binding ctla-4 and uses thereof |
WO2019140278A1 (en) | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
US20200405762A1 (en) | 2018-02-12 | 2020-12-31 | Fred Hutchinson Cancer Research Center | Cyclin a1 specific t cell receptors and uses thereof |
CA3091138A1 (en) | 2018-02-26 | 2019-08-29 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
JP2021519580A (ja) | 2018-03-28 | 2021-08-12 | セロ・セラピューティクス・インコーポレイテッドCERO Therapeutics, Inc. | キメラ貪食受容体のための発現ベクター、遺伝子改変宿主細胞およびそれらの使用 |
US20210023135A1 (en) | 2018-03-28 | 2021-01-28 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
WO2019191332A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
US20210223248A1 (en) | 2018-06-01 | 2021-07-22 | Fred Hutchinson Cancer Research Center | Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods |
US20220010268A1 (en) | 2018-12-27 | 2022-01-13 | Calysta, Inc. | Glycogen-null methanotrophs and uses thereof |
GB2613715B (en) | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
SG11202109745PA (en) | 2019-03-11 | 2021-10-28 | Hutchinson Fred Cancer Res | High avidity wt1 t cell receptors and uses thereof |
US20220409661A1 (en) | 2019-08-20 | 2022-12-29 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for wt-1 |
EP4038097A1 (en) | 2019-10-03 | 2022-08-10 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
EP4090367A1 (en) | 2020-01-13 | 2022-11-23 | T-Mobile USA, Inc. | Pattern recognition based on millimeter wave transmission in wireless communication networks |
CN115666639A (zh) | 2020-01-13 | 2023-01-31 | 阿帕特夫研究和发展有限公司 | 用于防止治疗性蛋白吸附到药物递送系统部件的方法和组合物 |
US11376320B2 (en) | 2020-03-05 | 2022-07-05 | Iowa State University Research Foundation, Inc. | Immunogenic and vaccine compositions against SARS-CoV-2 |
WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
EP4217387A2 (en) | 2020-09-24 | 2023-08-02 | Fred Hutchinson Cancer Center | Immunotherapy targeting sox2 antigens |
TW202214294A (zh) | 2020-09-30 | 2022-04-16 | 美商碩騰服務公司 | 具有hyaC及nanP缺失之新穎多殺性巴斯德氏菌株及疫苗 |
WO2022076353A1 (en) | 2020-10-06 | 2022-04-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating mage-a1-expressing disease |
IL305411A (en) | 2021-02-26 | 2023-10-01 | Kelonia Therapeutics Inc | Lymphocyte-targeted lentiviral vectors |
CN115216451A (zh) | 2021-04-16 | 2022-10-21 | 硕腾服务有限责任公司 | 伪狂犬病病毒疫苗 |
WO2022246244A1 (en) | 2021-05-21 | 2022-11-24 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
EP4376874A1 (en) | 2021-07-28 | 2024-06-05 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997018323A2 (en) * | 1995-11-16 | 1997-05-22 | Icos Corporation | Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity |
-
1995
- 1995-09-06 GB GBGB9518220.0A patent/GB9518220D0/en active Pending
-
1996
- 1996-09-06 PL PL96325427A patent/PL325427A1/xx not_active IP Right Cessation
- 1996-09-06 SK SK302-98A patent/SK30298A3/sk unknown
- 1996-09-06 EP EP96929433A patent/EP0856058B1/en not_active Expired - Lifetime
- 1996-09-06 CZ CZ1998656A patent/CZ292808B6/cs not_active IP Right Cessation
- 1996-09-06 BR BR9610168A patent/BR9610168A/pt not_active Application Discontinuation
- 1996-09-06 AU AU68846/96A patent/AU730220B2/en not_active Ceased
- 1996-09-06 IL IL12355396A patent/IL123553A0/xx unknown
- 1996-09-06 CN CN96198060A patent/CN1201492A/zh active Pending
- 1996-09-06 JP JP9510985A patent/JPH11511984A/ja not_active Ceased
- 1996-09-06 WO PCT/GB1996/002197 patent/WO1997009433A1/en not_active Application Discontinuation
- 1996-09-06 CA CA002231190A patent/CA2231190A1/en not_active Abandoned
-
1998
- 1998-03-05 NO NO980957A patent/NO980957L/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP0856058A1 (en) | 1998-08-05 |
NO980957L (no) | 1998-05-05 |
CA2231190A1 (en) | 1997-03-13 |
NO980957D0 (no) | 1998-03-05 |
AU6884696A (en) | 1997-03-27 |
SK30298A3 (en) | 2000-04-10 |
CN1201492A (zh) | 1998-12-09 |
GB9518220D0 (en) | 1995-11-08 |
PL325427A1 (en) | 1998-07-20 |
BR9610168A (pt) | 1998-08-11 |
CZ65698A3 (cs) | 2000-01-12 |
IL123553A0 (en) | 1998-10-30 |
WO1997009433A1 (en) | 1997-03-13 |
EP0856058B1 (en) | 2006-07-26 |
CZ292808B6 (cs) | 2003-12-17 |
AU730220B2 (en) | 2001-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11511984A (ja) | 細胞周期チェックポイント遺伝子 | |
Malkin | Germline p53 mutations and heritable cancer | |
CA2146965C (en) | Cyclin complex rearrangement and uses related thereto | |
US6620914B1 (en) | Transcription factor islet-brain 1 (IB1) | |
US6207452B1 (en) | Antibody of the anti-proliferation domain of human Bcl-2 | |
JPH11506907A (ja) | アポトーシスを変調する新規ペプチドおよび組成物 | |
EP1710582A2 (en) | Suppressor genes | |
US20080220455A1 (en) | p53-DEPENDENT APOPTOSIS-INDUCING PROTEIN AND METHOD OF SCREENING FOR APOPTOSIS REGULATOR | |
EP2298878A2 (en) | Compositions and methods for the diagnosis of cancer | |
JP2002516577A (ja) | 哺乳動物chk1エフェクター細胞周期チェックポイントタンパク質キナーゼ物質及び方法 | |
EP1263939B1 (en) | 18477, a human protein kinase and uses therefor | |
CA2408002A1 (en) | Enzymatic assays for screening anti-cancer agents | |
US20070172493A1 (en) | 12832, a novel human kinase-like molecule and uses thereof | |
US20080248009A1 (en) | Regulation of acheron expression | |
US6753158B1 (en) | Assays, agents, therapy and diagnosis relating to modulation of cellular DNA repair activity | |
RU2252256C2 (ru) | ГОМОЛОГИ (ATR) ПОЛИПЕПТИДА rad3, ПОЛИНУКЛЕОТИДЫ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И МАТЕРИАЛЫ | |
US20040241760A1 (en) | Kinesin-like proteins and methods of use | |
EP1454982A1 (en) | Mtehod of analyzing gene expression | |
US6632936B2 (en) | Cell-cycle checkpoint genes | |
US20060205020A1 (en) | Cell-cycle checkpoint genes | |
US6994992B1 (en) | Androgen-induced suppressor of cell proliferation and uses thereof | |
AU2008201172B2 (en) | Methods and Compositions for the Diagnosis of Cancer Susceptibilites and Defective DNA Repair Mechanisms and Treatment Thereof | |
EP1090987A1 (en) | Cell cycle regulatory factor | |
JP2002508180A (ja) | ヒトrad1核酸、ポリペプチド、検定、治療方法および手段 | |
WO2006034007A2 (en) | Methods of treating metabolic disorders by modulation of salt-inducible serine/threonine kinase 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060516 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060703 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20061002 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061107 |